Multicenter Phase II Feasibility Trial of High-Dose Tamoxifen in Patients With Refractory or Relapsed Multiple Myeloma (original) (raw)

Despite high-dose chemotherapy with autologous stem cell transplantation, most patients with multiple myeloma relapse and eventually die. This Phase II feasibility trial tested high-dose tamoxifen in patients with relapsed or refractory multiple myeloma following prior chemotherapy. Findings indicated no substantial estrogen receptor expression in most tumor cells and no significant therapeutic activity of tamoxifen against multiple myeloma, leading to the conclusion that high-dose oral tamoxifen is not an effective treatment for this patient population.